Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data
Dyne Therapeutics is making significant strides in treating genetically driven neuromuscular diseases, highlighted by positive long-term cardiopulmonary data from the Phase 1/2 DELIVER trial of z-rostudirsen in Duchenne muscular dystrophy (DMD), the initiation of the pivotal Phase 3 HARMONIA trial for z-basivarsen in myotonic dystrophy type 1 (DM1), and ongoing registrational efforts supporting potential accelerated … Read more